Biweekly SOLAR, as First-line C/T in Pts With Gastric, Pancreatic and Biliary Cancers

Inclusion Criteria:

* Pathologically confirmed adenocarcinoma or carcinoma of the stomach, pancreas and biliary tract with unresectable, recurrence or metastatic disease.
* No prior systemic chemotherapy except adjuvant chemotherapy that has completed 6 months prior enrollment.
* Palliative RT to bone but not the primary, main tumor site is permitted.
* At least one measurable lesion over non-radiated site.
* Aged between 20 to 70 years old.
* ECOG Performance Status \<= 1.
* Life expectancy greater than 12 weeks.
* Adequate bone marrow function : absolutely neutrophil count \>= 1.5 x 109/L or WBC \>= 4 x 109/L, hemoglobin \>= 9 g/dl, platelet count 100 x 109/L
* Adequate liver function : ALT \<= 2.5 x ULN and Bilirubin \< 1.5 x ULN
* Adequate renal function: creatinine \< 1.5 x ULN and calculated eGFR\> 50 mL/min.

Exclusion Criteria:

* Major surgery within four weeks prior to study enrolment.
* Patient with Ampulla vater cancer is excluded.
* Patients with suspicious or history of CNS metastasis.
* Patients who with active or uncontrolled infections.
* Patients who have history of myocardial infarction or unstable angina within 6 months before entry.
* Patients with concomitant illness that might be aggravated by chemotherapy.
* Patients who are pregnant or with breast feeding.
* Other concomitant or previously malignancy within 3 yrs except for in situ cervix cancer or squamous cell carcinoma of the skin, stage 0-I colon or breast treated by surgery only and without evidence of relapsed tumor.
* Mental status is not fit for clinical trial
* Fertile men and women unless using a reliable and appropriate contraceptive method.